王欣琰, 聂成洋, 晁亮, 王辉, 闻俊, 洪战英. P-糖蛋白调控的葛根-知母药对活性成分在体肠吸收和体内药动学研究J. 药学学报, 2025, 60(12): 3775-3782. DOI: 10.16438/j.0513-4870.2025-0982
引用本文: 王欣琰, 聂成洋, 晁亮, 王辉, 闻俊, 洪战英. P-糖蛋白调控的葛根-知母药对活性成分在体肠吸收和体内药动学研究J. 药学学报, 2025, 60(12): 3775-3782. DOI: 10.16438/j.0513-4870.2025-0982
WANG Xin-yan, NIE Cheng-yang, CHAO Liang, WANG Hui, WEN Jun, HONG Zhan-ying. Study on P-glycoprotein-mediated intestinal absorption and in vivo pharmacokinetics of bioactive components in the Gegen-Zhimu herb pairJ. Acta Pharmaceutica Sinica, 2025, 60(12): 3775-3782. DOI: 10.16438/j.0513-4870.2025-0982
Citation: WANG Xin-yan, NIE Cheng-yang, CHAO Liang, WANG Hui, WEN Jun, HONG Zhan-ying. Study on P-glycoprotein-mediated intestinal absorption and in vivo pharmacokinetics of bioactive components in the Gegen-Zhimu herb pairJ. Acta Pharmaceutica Sinica, 2025, 60(12): 3775-3782. DOI: 10.16438/j.0513-4870.2025-0982

P-糖蛋白调控的葛根-知母药对活性成分在体肠吸收和体内药动学研究

Study on P-glycoprotein-mediated intestinal absorption and in vivo pharmacokinetics of bioactive components in the Gegen-Zhimu herb pair

  • 摘要: 探究知母提取物对葛根素肠道吸收和药代动力学过程的影响, 以期从P-gp调控角度阐释葛根-知母药对配伍应用的科学内涵。基于HPLC-UV技术建立生物样本中葛根素定量分析方法, 采用大鼠单向肠灌流模型和药代动力学方法, 以经典P-gp抑制剂维拉帕米为对照, 考察知母提取物对葛根素体内吸收和代谢过程的影响。结果所建立的肠道灌流液和血浆样本中葛根素分析方法符合生物样品定量分析要求。葛根素在十二指肠的KaPapp值显著高于空肠和回肠肠段(P < 0.000 1); 与知母提取物或维拉帕米联用后, 葛根素在十二指肠的KaPapp值显著增大(P < 0.000 1); 与高剂量知母提取物和维拉帕米联合给药后, 葛根素在大鼠体内的Cmax分别显著增加至(1.017 ± 0.25) µg·mL-1和(1.827 ± 0.87) µg·mL-1 (P < 0.05); AUC0-∞亦显著增加(P < 0.05), 分别为单独给药葛根素的1.37倍和2.25倍。葛根素在大鼠十二指肠段的吸收最佳, 知母提取物通过抑制P-gp的外排作用, 促进葛根素在十二指肠段的吸收, 增加其血药浓度, 有效提高葛根素的口服生物利用度, 阐明了葛根-知母药对配伍应用的科学内涵。本实验获得海军军医大学伦理委员会批准(批准号: NMUARE-21077)。

     

    Abstract: To explore the effects of Zhimu extract on the absorption and pharmacokinetic process of puerarin, thus to elucidate the scientific connotation of the compatibility application of Gegen-Zhimu herb pair from the perspective of P-glycoprotein (P-gp) regulation, a rapid and sensitive quantification method for puerarin in biological samples was established based on HPLC-UV technology. Combined with the rat single-pass intestinal perfusion model and pharmacokinetic experiments, with the classic P-gp inhibitor verapamil as control, the effects of Zhimu extract on the absorption and metabolism process of puerarin were investigated. The established HPLC method for puerarin in intestine perfusate and plasma samples met the requirements for quantitative analysis of biological samples. The Ka and Papp values of puerarin in the duodenal segment were significantly higher than those in the jejunal and ileal segments (P < 0.000 1). Co-administration with Zhimu extract or verapamil significantly increased the Ka and Papp values of puerarin in the duodenal segment (P < 0.000 1). Co-administration with high-dose Zhimu extract or verapamil significantly increased the Cmax of puerarin in rats to (1.017 ± 0.25) µg·mL-1 and (1.827 ± 0.87) µg·mL-1 (P < 0.05), respectively, and AUC0-∞ also significantly increased (P < 0.05), reaching 1.37-fold and 2.25-fold that of the puerarin group, respectively. Puerarin is best absorbed in the duodenal segment; by inhibiting the efflux of P-gp, Zhimu extract can promote the absorption of puerarin in the duodenal segment, increase its plasma concentration, and effectively improve the oral bioavailability of puerarin, which suggests the mechanism underlying the compatibility of Gegen-Zhimu herb pair. This experiment was approved by the Animal Ethics Committee of Naval Medical University (approval No.: NMUARE-21077).

     

/

返回文章
返回